COMPOUND PROFILE / SMALL MOLECULES
Orforglipron is an oral small-molecule GLP-1 receptor agonist branded Foundayo.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Orforglipron is an oral small-molecule GLP-1 receptor agonist branded Foundayo.
It activates GLP-1 signalling without a peptide structure.
Randomised clinical programmes support approved weight-management uses; population and jurisdiction affect the label.
Receptor studies characterised oral activity.
Gastrointestinal effects and pancreatic, gallbladder, dehydration and thyroid-related warnings are relevant.
FDA approved Foundayo for weight management in April 2026. MHRA authorised weight management and type 2 diabetes in August 2026.
The supplied Orforglipron profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Follow the cited records and registered research. Profiles remain research drafts.